Company prepares to advance to Phase 2 clinical trial in early 2025 HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March…
Appoints Simon Harnest as Chief Financial Officer to advance capital markets and corporate development strategy supporting TOS-358, the Company’s lead…
SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing…
Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies at global biopharmaceutical companies Sara…
- PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities…
DURHAM, N.C.and SEATTLE, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally…
Calgary, Alberta--(Newsfile Corp. - January 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…
PORTSMOUTH, N.H., Jan. 27, 2025 /PRNewswire/ -- MediSpend, a global technology company providing best-in-class solutions for the life sciences industry,…
Final Imperative Trial Data Show the Zoom System Delivered the Fastest Median Case Time in A Well-Controlled, Rigorous Study1CAMPBELL, Calif.--(BUSINESS…
- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the…